{'fraction_non_alphanumeric': 0.03723404255319149, 'fraction_numerical': 0.015957446808510637, 'mean_word_length': 5.307262569832402, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of diumancal and decursinol on 5-hydroxytryptamine level in rat brain.

In an attempt to elucidate whether changes in serotonin (5-HT) levels were involved in the behavioral changes, monoamine concentrations in three brain regions (striatum, frontal cortex and hypothalamus) obtained from diumancal (0,1 mg/kg;1 mg/kg) and decursinol (1mg/kg;10mg/kg) -treated rats were quantified by spectrofluorometer, and compared with monoamine concentrations in verapamil-treated animals (2 mg/kg; 15 mg/kg). It was found that both 2H1 benzopyrane 2-on derivatives diumancal and decursinol, a novel calcium antagonists increase 5-HT levels in three brain regions as verapamil does. The highest concentration of serotonin was observed in frontal cortex and striatum after administration of 10 mg/kg-dose decursinol. Diumancal at high dose (1 mg/kg) increased the level of neurotransmitter more remarkably in hypothalamus. Taking into account the activating effect of diumancal and decursinol on serotonergic system they may have a place in the treatment of some depressive disorders. More detailed investigations are required though.